Meet The Attys Guiding Omega Therapeutics Through Ch. 11

Biotechnology company Omega Therapeutics, which hit Chapter 11 in Delaware on Monday with more than $140 million of debt and a restructuring agreement with an affiliate of its controlling stockholder, has...

Already a subscriber? Click here to view full article